🇺🇸 Zenapax in United States

451 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Transplant Rejection — 79 reports (17.52%)
  2. Drug Ineffective — 54 reports (11.97%)
  3. Kidney Transplant Rejection — 50 reports (11.09%)
  4. Complications Of Transplanted Kidney — 47 reports (10.42%)
  5. Alopecia — 40 reports (8.87%)
  6. Condition Aggravated — 39 reports (8.65%)
  7. Transplant Dysfunction — 38 reports (8.43%)
  8. Ovarian Cyst — 35 reports (7.76%)
  9. Pneumonia — 35 reports (7.76%)
  10. Acne — 34 reports (7.54%)

Source database →

Other Neuroscience approved in United States

Frequently asked questions

Is Zenapax approved in United States?

Zenapax does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Zenapax in United States?

National Institute of Neurological Disorders and Stroke (NINDS) is the originator. The local marketing authorisation holder may differ — check the official source linked above.